Genetesis is a cutting-edge brand that specializes in magnetocardiography (MCG) and revolutionizes cardiac imaging. MCG is a medical imaging technique that measures the heart's electrical activity through magnetic fields using highly sensitive devices. Genetesis' flagship product, CardioFlux, offers the fastest and non-invasive solution to detect myocardial ischemia, enabling the early identification of functionally significant ischemia at its earliest stages.

Overcoming earlier limitations, Genetesis has developed CardioFlux MCG, which integrates advanced sensing technology and machine learning. This device only requires a standard-sized room and a single standard outlet, making it more practical and accessible for clinical practice. With MCG, Genetesis provides magnetic field maps that highlight potential abnormalities in cardiac conduction.

These maps can detect changes in ion conduction, action potential, and amplitudes, allowing for early detection of cardiac dysfunction. Moreover, MCG is particularly sensitive to tangential and vortex currents, providing rich information about ischemia. Genetesis's MCG technology has shown promising results in diagnosing coronary artery disease (CAD) and coronary microvascular dysfunction (CMD), even outperforming traditional stress testing methods.

Additionally, MCG has the potential to significantly impact areas such as direct diagnosis, patient monitoring, and fetal observation. With an impressive portfolio of clinical trials and a dedicated team, Genetesis is at the forefront of transforming cardiac imaging and improving patient outcomes. Keep up with the latest developments from Genetesis by following them on social media